Private equity firm Avista Capital Partners has hired Hakan Bjorklund, the departing Chief Executive Officer of Nycomed, as Healthcare Operating Executive.
Bjorklund worked closely with Avista on the development of Nycomed during Avista’s ownership of the company, which was recently sold to Takeda Pharmaceuticals Company Limited for EUR9.6 billion.
Under Bjorklund’s leadership, Nycomed was transformed from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America. In 2006, Bjorklund led the integration of Altana Pharmaceutical, a German-based company that Nycomed purchased for EUR4.2 billion. He was also instrumental in growing Nycomed in emerging markets, most recently through the acquisition of Guangdong Techpool Bio-Pharma Co, Ltd, a fast growing Chinese bio-pharmaceutical company, in 2010.
Thompson Dean, Co-Managing Partner and Chief Executive Officer of Avista, says: "We are delighted to welcome Hakan to Avista. One of the top pharmaceutical executives in Europe, he possesses a deep understanding of the global healthcare market. Having worked closely with him for many years, I know that Hakan will bring extensive strategic, operational and investment expertise to Avista as well as strong relationships throughout the global healthcare sector."
Newton Aguiar, the partner in charge of Avista’s European operations, says: "We are looking forward to working with Hakan on healthcare investments both in Europe and throughout the world. Hakan built Nycomed into one of the fastest growing global pharmaceutical companies, in part, by expanding its presence in key emerging markets, particularly in Russia/CIS and Latin America. His experience will be invaluable to the healthcare management teams in Avista’s portfolio as they seek to grow their own businesses."
Bjorklund says: "This is a very exciting opportunity. Avista is a leading private equity healthcare investor with a long track record of successful investments in the pharmaceutical, medical device, and healthcare services sectors. As CEO of Nycomed, I was deeply impressed by the sector expertise and supportive ownership philosophy that Avista brings to its investments. I am looking forward to helping other leading healthcare companies reach their full potential as a member of the Avista team."
Before joining Nycomed, Bjorklund was Regional Director at Astra (now AstraZeneca) and, earlier, President of Astra Draco. He is a member of the Board of Directors of Coloplast A/S, Lundbeck A/S, and Atos Medical AB. He was also a director at Danisco A/S until its recent acquisition by Dupont. He holds a PhD in Neuroscience from Karolinska Institutet in Sweden.
